Home/Pipeline/Cambritaxestat (IOA-289)

Cambritaxestat (IOA-289)

Oncology (unspecified)

Phase 2Active

Key Facts

Indication

Oncology (unspecified)

Phase

Phase 2

Status

Active

Company

iOnctura

About iOnctura

iOnctura is a private, clinical-stage biotech developing a pipeline of novel, oral small molecules targeting the tumor microenvironment to overcome stroma and immune-mediated resistance in challenging cancers. Its lead programs include roginolisib (IOA-244), a first-in-class allosteric PI3Kδ modulator, and cambritaxestat (IOA-289), the only autotaxin inhibitor in clinical development for oncology. With a seasoned leadership team, over €100M in private financing, and two programs in mid-stage clinical development, the company is positioned to address significant unmet needs in oncology with potentially differentiated, precision therapies.

View full company profile

Therapeutic Areas

Oncology

Other Oncology (unspecified) Drugs

Drug	Company	Phase	Status
Oncology Vaccine Program	CHAIN Biotech	Pre-clinical	Active
ARX305	NovoCodex Biopharmaceuticals	Phase 1	Active
ARX788	NovoCodex Biopharmaceuticals	Phase 1	Active
Cancer Immunotherapy Nanotherapeutic	Flashpoint Therapeutics	Phase 1	Active
GRWD5769	Greywolf Therapeutics	Phase 1/2	Active
Platform-derived Program(s)	Immuto Scientific	Discovery/Pre-clinical	Active
MBT Oncology Program	Ionic Pharmaceuticals	Pre-clinical	Active
ISB 2301	Ichnos Glenmark Innovation	Preclinical	Active
GRC 65327	Ichnos Glenmark Innovation	Preclinical	Active
Platform-Derived Pipeline	Phinomics	Discovery/Pre-clinical	Active
Lead Small-Molecule Inhibitor	Eris Biotech	Pre-clinical	Active
Orotecan™	Edison Oncology	Phase 1/2a	Active